Allena is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
March 9 - March 10, 2021
H.C. Wainwright Global Life Sciences ConferencePre-recorded presentation will become available for on-demand viewing at 7:00 a.m. ET on Tuesday, March 9th.
March 1 - March 3, 2021
Cowen’s 41st Annual Health Care ConferenceManagement participating in panel discussion, titled “Kidney Disease Panel” beginning at 3:20pm ET on March 3rd.